Ignite Creation Date:
2024-05-05 @ 6:31 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00490360
Status:
COMPLETED
Last Update Posted:
2007-06-22
First Post:
2007-06-21
Brief Title:
Neoadjuvant Chemotherapy for Resectable Cancer of the Pancreatic Head
Sponsor:
University of Zurich
Organization:
University of Zurich
Study Overview
Official Title:
Neoadjuvant Chemotherapy for Resectable Cancer of the Pancreatic Head
Status:
COMPLETED
Status Verified Date:
2007-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Neodajuvant chemotherapy with gemcitabine cisplatin is applied to patients with resectable cancer of pancreatic head
Detailed Description:
Neodajuvant chemotherapy with gemcitabine cisplatin is applied to patients with resectable cancer of pancreatic head Two cycles of chemotherapy are given on day 1 and 15 each After restaging excludes disease progression a standard Whipple procedure is performed
Staging and restaging procedures include abdominal CT diagnostic laparoscopy PETCT tumor markers CEA CA 19-9 and assessment of the quality of life by the QLQ-30
Trial with medicinal product
Staging and restaging procedures include abdominal CT diagnostic laparoscopy PETCT tumor markers CEA CA 19-9 and assessment of the quality of life by the QLQ-30
Trial with medicinal product
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None